Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Key Biosimilars Events of February 2026 

Shots:  Regulatory momentum accelerated globally with multiple biosimilars securing key approvals and positive opinions, including Sandoz’s Enzeevu (Eylea biosimilar) in the US and Canada, Accord BioPharma’s Filkri (Neupogen biosimilar) US FDA approval, EC approvals for Gotenfia (Simponi biosimilar) and Ranluspec (Lucentis biosimilar), and CHMP positive opinions for tocilizumab and insulin biosimilars.  Strategic partnerships expanded regional access as companies including Alvotech, Bio-Thera Solutions, Formycon,…
March 3, 2026

Read more

INSIGHTS+

Key Biosimilars Events of January 2026   

Shots:  Global biosimilar activity accelerated across ophthalmology, oncology, immunology, and diabetes, with new or advancing alternatives to Lucentis, Eylea, Stelara, Lantus, Avastin, Opdivo, and Neulasta, expanding patient access across Europe, the US, India, Canada, Ghana, and MENA  Regulatory and commercialization momentum remained strong, marked by FDA, EC, Health Canada, and Ghana FDA milestones, alongside Samsung Bioepis’…
February 3, 2026

Read more

VIEWPOINTS

Tariffs, Compliance, and the Future of Drug Pricing: A Conversation with Jesse Mendelsohn from Model N 

Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…
November 24, 2025

Read more

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots:  Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery  Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding  Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

VIEWPOINTS

Enhancing Accessibility to Medicine: Joshua Salsi from Biocon Biologics in Conversation with PharmaShots 

Shots:  Biocon Biologics’ Yesintek, biosimilar to Stelara, has secured broad market access through inclusion in the formularies of all major pharmacy benefit managers (PBMs)  Yesintek offers strong financial support and a smooth transition process, positioning it as a preferred option for patients needing ustekinumab therapy  Joshua Salsi, Head of North America Commercial at Biocon Biologics,…
August 4, 2025

Read more